It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...